Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Cancer MedicineJun 5, 2026
Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment‐Naive Chronic Lymphocytic Leukemia: A Real‐World Propensity Score‐Matched Study

Clinical Context

We think this might be relevant to the clinical guidance for CLL-IPI (Chronic Lymphocytic Leukemia).

DiabetologiaJun 5, 2026
MASLD, diabetes and PMOS across the female life stages

Clinical Context

We think this might be relevant to the clinical guidance for CLL-IPI (Chronic Lymphocytic Leukemia).

Cancer MedicineJun 5, 2026
Descriptive Epidemiology and Prognosis of Pediatric Acute Leukemia in the Afro‐Descendant Population of the French West Indies and French Guiana

Clinical Context

We think this might be relevant to the clinical guidance for CLL-IPI (Chronic Lymphocytic Leukemia).

CLL-IPI

CLL-IPIInternational Prognostic Index for CLL

Demographics & Serology

years
mg/L

Cutoff: 3.5 mg/L

Genetics & Staging

Awaiting Data

The CLL-IPI integrates genetic, biochemical, and clinical markers to stratify newly diagnosed CLL.

Scoring Highlights

  • TP53 aberration: 4 points
  • IGHV unmutated: 2 points
  • Beta-2M > 3.5 mg/L: 2 points
Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Baseline risk stratification for all patients with newly diagnosed CLL.
Aiding the decision of when to initiate treatment (though not a substitute for iwCLL treatment indications).
Selecting between chemo-immunotherapy (FCR/BR) and novel agents (BTK inhibitors or Venetoclax).

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the iwCLL 2018 Response, CLL-IPI or the MRD Assessment Threshold Interpreter to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

iwCLL 2018 Response
CLL-IPI
MRD Assessment
Sedlis/Peters Criteria
Oncotype DX Recurrence
FIGO 2023
RANO 2.0
mRECIST
NSCLC GPA
Mayo 20/2/20
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.